PLASMA Act

The PLASMA Act (S 694) modifies Medicare Part D drug discount rules for plasma-derived products - biological drugs made from human blood plasma. It establishes a phased reduction in the discount rate these drugs must offer to Medicare beneficiaries, starting at 99% of the negotiated price in 2026 and gradually decreasing to 80% by 2032. This affects manufacturers of plasma-derived drugs covered under Medicare Part D and beneficiaries who meet specific out-of-pocket cost thresholds. The bill excludes certain low-income beneficiaries and small manufacturers from these provisions. The policy change directly alters how drug costs are calculated for these specific medications under Medicare.